Document Detail


The effects of sildenafil and acetazolamide on breathing efficiency and ventilatory control during hypoxic exercise.
MedLine Citation:
PMID:  19337745     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The reduced arterial oxygen tension at high altitude impairs the ability to work. Acetazolamide improves arterial oxygen saturation (SaO(2)) by increasing ventilation but is associated with an increased work and cost of breathing. Depending on the settings, sildenafil can also increases SaO(2) possibly through a reduction in pulmonary hypertension and interstitial edema, which could improve ventilation-perfusion matching. The objective of this study is to determine the effects of acetazolamide and sildenafil on ventilatory control and breathing efficiency (V(E)/VCO(2)) during submaximal steady-state hypoxic exercise in healthy individuals. Following 18 h of hypoxic exposure in an altitude tent at an oxygen concentration of 12.5% (simulated altitude of 4,300 m), 15 participants performed 10 min of hypoxic exercise on a stationary bicycle at 40% of their sea level peak oxygen uptake (VO(2)) while randomly receiving sildenafil 40 mg (SIL), acetazolamide 125 mg (ACZ) or a placebo (PLA). There was no difference in VO(2) during exercise between conditions while SaO(2) was greater with acetazolamide compared to both placebo and sildenafil. Acetazolamide increased ventilation (PLA 49.0 +/- 3.2, SIL 47.7 +/- 3.1, ACZ 52.1 +/- 3.0 l/min) and reduced end-tidal CO(2) (P(ET)CO(2)) (PLA 32.1 +/- 0.8, SIL 32.8 +/- 0.9, ACZ 29.2 +/- 0.7 mmHg) compared to placebo and sildenafil. Breathing was less efficient with acetazolamide (increased V(E)/VCO(2)) in comparison to placebo and sildenafil (PLA 41.5 +/- 1.0, SIL 40.4 +/- 1.3, ACZ 45.4 +/- 1.0) while sildenafil did not change V(E)/VCO(2) during hypoxic exercise. In conclusion, acetazolamide increased ventilation and reduced breathing efficiency while sildenafil did not affect breathing efficiency despite a trend toward a blunted ventilatory response, possibly due to a reduction in pulmonary hypertension and/or ventilatory drive, during submaximal hypoxic exercise in healthy individuals.
Authors:
Sophie Lalande; Eric M Snyder; Thomas P Olson; Minelle L Hulsebus; Marek Orban; Virend K Somers; Bruce D Johnson; Robert P Frantz
Related Documents :
23971695 - The promises and challenges of the use of genomics in the prescription of exercise for ...
12481095 - A rice mutant defective in si uptake.
6811525 - Fibrinopeptide a after strenuous physical exercise at high altitude.
16179365 - Economy of locomotion in high-altitude tibetan migrants exposed to normoxia.
18575095 - Minutes in motion: motivating a community to move.
12370555 - Onset of electrical stimulation leg cycling in individuals with paraplegia.
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2009-04-01
Journal Detail:
Title:  European journal of applied physiology     Volume:  106     ISSN:  1439-6327     ISO Abbreviation:  Eur. J. Appl. Physiol.     Publication Date:  2009 Jul 
Date Detail:
Created Date:  2009-06-09     Completed Date:  2009-08-19     Revised Date:  2013-11-06    
Medline Journal Info:
Nlm Unique ID:  100954790     Medline TA:  Eur J Appl Physiol     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  509-15     Citation Subset:  IM    
Affiliation:
Division of Cardiovascular Diseases, Mayo Clinic, College of Medicine, Rochester, MN 55905, USA. lalande.sophie@mayo.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acetazolamide / administration & dosage*
Adult
Anaerobiosis / drug effects,  physiology*
Diuretics / administration & dosage
Exercise Test
Female
Humans
Male
Oxygen Consumption / drug effects,  physiology*
Physical Exertion / drug effects,  physiology*
Piperazines / administration & dosage*
Pulmonary Ventilation / drug effects,  physiology*
Purines / administration & dosage
Respiratory Mechanics / drug effects,  physiology*
Sulfones / administration & dosage*
Vasodilator Agents / administration & dosage
Grant Support
ID/Acronym/Agency:
HL65176/HL/NHLBI NIH HHS; HL71478/HL/NHLBI NIH HHS; MO1-RR00585/RR/NCRR NIH HHS; R01 HL071478/HL/NHLBI NIH HHS; R01 HL071478-05/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Diuretics; 0/Piperazines; 0/Purines; 0/Sulfones; 0/Vasodilator Agents; 3M7OB98Y7H/sildenafil; 59-66-5/Acetazolamide
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Vasculitis : Histopathology and differential diagnosis.
Next Document:  Aerobic high intensity one and two legs interval cycling in chronic obstructive pulmonary disease: t...